MX2020009787A - Combinacion de anticuerpo anti factor del crecimiento del hepatocito (hgfr) y receptor para el factor de crecimiento epidermico (hegfr) para el tratamiento de un tumor y/o metastasis. - Google Patents
Combinacion de anticuerpo anti factor del crecimiento del hepatocito (hgfr) y receptor para el factor de crecimiento epidermico (hegfr) para el tratamiento de un tumor y/o metastasis.Info
- Publication number
- MX2020009787A MX2020009787A MX2020009787A MX2020009787A MX2020009787A MX 2020009787 A MX2020009787 A MX 2020009787A MX 2020009787 A MX2020009787 A MX 2020009787A MX 2020009787 A MX2020009787 A MX 2020009787A MX 2020009787 A MX2020009787 A MX 2020009787A
- Authority
- MX
- Mexico
- Prior art keywords
- hgfr
- antibody fragment
- extracellular portion
- hgfr antibody
- metastasis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102018000003875A IT201800003875A1 (it) | 2018-03-22 | 2018-03-22 | Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi |
| PCT/IB2019/052307 WO2019180658A1 (en) | 2018-03-22 | 2019-03-21 | Combination of anti-hgfr antibody and hegfr for the treatment of a tumor and/or metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009787A true MX2020009787A (es) | 2020-11-09 |
Family
ID=62530500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009787A MX2020009787A (es) | 2018-03-22 | 2019-03-21 | Combinacion de anticuerpo anti factor del crecimiento del hepatocito (hgfr) y receptor para el factor de crecimiento epidermico (hegfr) para el tratamiento de un tumor y/o metastasis. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11814433B2 (enExample) |
| EP (1) | EP3768710A1 (enExample) |
| JP (1) | JP7381555B2 (enExample) |
| KR (1) | KR102988957B1 (enExample) |
| CN (1) | CN112041340A (enExample) |
| AU (1) | AU2019240274B2 (enExample) |
| BR (1) | BR112020018981A8 (enExample) |
| CA (1) | CA3093513A1 (enExample) |
| IL (1) | IL277476B2 (enExample) |
| IT (1) | IT201800003875A1 (enExample) |
| MX (1) | MX2020009787A (enExample) |
| SG (1) | SG11202008612XA (enExample) |
| WO (1) | WO2019180658A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017135251A1 (ja) * | 2016-02-02 | 2017-08-10 | 国立研究開発法人物質・材料研究機構 | 強磁性トンネル接合体、これを用いた磁気抵抗効果素子及びスピントロニクスデバイス並びに強磁性トンネル接合体の製造方法 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025188676A1 (en) * | 2024-03-04 | 2025-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Genetic engineering of cells for secretion of therapeutic antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602006018354D1 (de) | 2005-12-05 | 2010-12-30 | Pfizer Prod Inc | Verfahren zur behandlung von abnormalem zellwachstum |
| ES2368864T3 (es) * | 2006-02-06 | 2011-11-23 | Metheresis Translational Research Sa | Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes. |
| CN101914161B (zh) * | 2010-08-13 | 2013-12-11 | 四川大学 | 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途 |
| ITTO20130012A1 (it) * | 2013-01-09 | 2014-07-10 | Metheresis Translational Res S A | Nuovi frammenti anticorpali, relative composizioni ed usi |
-
2018
- 2018-03-22 IT IT102018000003875A patent/IT201800003875A1/it unknown
-
2019
- 2019-03-21 US US16/982,330 patent/US11814433B2/en active Active
- 2019-03-21 AU AU2019240274A patent/AU2019240274B2/en active Active
- 2019-03-21 MX MX2020009787A patent/MX2020009787A/es unknown
- 2019-03-21 IL IL277476A patent/IL277476B2/en unknown
- 2019-03-21 EP EP19721054.5A patent/EP3768710A1/en active Pending
- 2019-03-21 CA CA3093513A patent/CA3093513A1/en active Pending
- 2019-03-21 SG SG11202008612XA patent/SG11202008612XA/en unknown
- 2019-03-21 BR BR112020018981A patent/BR112020018981A8/pt unknown
- 2019-03-21 JP JP2021500367A patent/JP7381555B2/ja active Active
- 2019-03-21 KR KR1020207030214A patent/KR102988957B1/ko active Active
- 2019-03-21 WO PCT/IB2019/052307 patent/WO2019180658A1/en not_active Ceased
- 2019-03-21 CN CN201980020753.XA patent/CN112041340A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102988957B1 (ko) | 2026-07-08 |
| IT201800003875A1 (it) | 2019-09-22 |
| EP3768710A1 (en) | 2021-01-27 |
| US11814433B2 (en) | 2023-11-14 |
| IL277476A (en) | 2020-11-30 |
| WO2019180658A1 (en) | 2019-09-26 |
| JP2021518170A (ja) | 2021-08-02 |
| CN112041340A (zh) | 2020-12-04 |
| BR112020018981A8 (pt) | 2022-06-28 |
| JP7381555B2 (ja) | 2023-11-15 |
| KR20200135449A (ko) | 2020-12-02 |
| AU2019240274A1 (en) | 2020-10-15 |
| BR112020018981A2 (pt) | 2021-01-05 |
| AU2019240274B2 (en) | 2025-04-24 |
| IL277476B2 (en) | 2026-05-01 |
| US20210070868A1 (en) | 2021-03-11 |
| CA3093513A1 (en) | 2019-09-26 |
| SG11202008612XA (en) | 2020-10-29 |
| RU2020129465A (ru) | 2022-04-22 |
| IL277476B1 (en) | 2026-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003728A1 (es) | Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf. (divisional solicitud 201701000) | |
| CL2019000277A1 (es) | Tratamiento conjunto contra el cáncer. | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| MX2023014569A (es) | Anticuerpos anti-sirpa. | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| MX2017001599A (es) | Anticuerpos novedosos y sus usos. | |
| BR112014028941A2 (pt) | combinação de terapia envolvendo anticorpos contra claudin 18.2 para o tratamento de câncer | |
| MX386491B (es) | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. | |
| BR112014028948A2 (pt) | combinação de terapia envolvendo anticorpos contra claudin 18.2 para o tratamento de câncer | |
| MX360497B (es) | Anticuerpos de proteina accesoria del receptor de interleucina-1 antihumana (il1 rap) y usos de los mismos. | |
| BR112017015627A2 (pt) | Compostos de piperidina ureia substituída com 4- metilsulfonila para o tratamento de cardiomiopatia dilatada (dcm) | |
| CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
| MX2021008131A (es) | Metodos y composiciones para el tratamiento de la enfermedad de fabry. | |
| PH12017500032B1 (en) | Improved aã protofibril binding antibodies | |
| CO6571892A2 (es) | Composiciones y métodos para el diagnostico y tratamiento de tumores | |
| DOP2017000248A (es) | PROTEÍNA DE UNIÓN A RGMa Y SU USO | |
| MX2017003211A (es) | Anticuerpos anti-met y composiciones. | |
| CL2024000459A1 (es) | Tubulisinas y conjugados de proteína-tubulisina. | |
| EA202092302A1 (ru) | Антитела к trem-1 и их применения | |
| CY1126559T1 (el) | Παραδειγμα θεραπειας για θεραπεια συνδυασμου anti-cd19 αντισωματος και βενετοκλαξης | |
| ECSP20076576A (es) | Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas | |
| PE20221830A1 (es) | Anticuerpos especificos contra la claudina 18.2 tumoral | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| MX2019005491A (es) | Anticuerpo que enlaza especificamente a cd66c y uso del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: VERTICAL BIO AG |